ClinicalTrials.gg
WithdrawnNCT01199250Updated Aug 14, 2024

Biomarkers in Samples From Patients With Endometrial Cancer

An observational study in Lynch Syndrome, Recurrent Uterine Corpus Carcinoma and Stage I Uterine Corpus Cancer, sponsored by Gynecologic Oncology Group. Withdrawn at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Gynecologic Oncology Group · Observational

How we know

Why this study was withdrawn
Not a treatment/applicable clinical trial

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
0
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States — 21 open to participants now, 33 under way, 2 of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · United States.

Enrollment
28th of 29
0 · median 300
Started
2010
with 1 other
Observational
29 of 72
8 open now
Registered
12th of 72
by date

Among the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, this one is the 28th largest by enrollment of the 29 observational ones that give a count, is one of 2 that started in 2010, is one of 29 observational ones, and was the 12th registered.

Colorectal Neoplasms, Hereditary Nonpolyposis

147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 61 are open to participants now.

Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →

Open to participants now

21 of the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, or all of them as a file.
02

Study summary

This research study is studying biomarkers in samples from patients with endometrial cancer. Studying samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. Assess the frequency and spectrum of mutations in fibroblast growth factor receptor 2 (FGFR2) in low-, intermediate-, and/or high-risk endometrioid endometrial cancer from GOG-0210. (Project 1) II. Determine the relationship between FGFR2 mutation and clinicopathologic variables including disease-free and overall survival in low-, intermediate-, and/or high-risk endometrial cancer from GOG-0210. (Project 1) III. Identify the cognate FGF ligands and receptors expressed in normal endometrium and endometrial cancers, and examine their expression on multiple tissue microarrays for GOG-0210 to determine their association with clinical outcome. (Project 1) IV. Identify epigenetic biomarkers (differential methylation of CpG island loci) associated with recurrence and disease progression in endometrioid endometrial cancer from Washington University School of Medicine (WUSM). (Project 2) V. Confirm epigenetic biomarkers (differential methylation of CpG island loci) associated with recurrent and disease progression in endometrioid endometrial cancer from GOG-0210. (Project 2) VI. Define the performance (sensitivity and specificity) of epigenetic biomarkers associated with recurrence and disease progression in endometrioid endometrial cancer from an independent cohort of cases from GOG-0210. (Project 2) VII. Develop a molecular screening regimen to compliment family history risk assessment to identify carriers of Hereditary Non-Polyposis Colorectal Cancer (HNPCC)-related and other forms of inherited endometrial cancer from GOG-0210 that was not ascertained by family history. (Project 3) VIII. Estimate the prevalence of HNPCC-related and other forms of inherited endometrial cancer in GOG-0210. (Project 3) IX. Define the relationship between defective DNA mismatch repair and clinical and epidemiological factors in GOG-0210. (Project 3) X. Determine the clinicopathologic significance of mismatch-repair defects including associations with disease-free and overall survival in GOG-0210. (Project 3) XI. Assess expression of five candidate ERK1/2 substrates in the normal endometrium, primary endometrial cancers (from WUSM and GOG-0210) and endometrial cancer cell lines and determine if substrate phosphorylation is ERK-dependent. (Project 4) XII. Determine the relationship between ERK substrate-phosphorylation status and upstream ERK-signaling pathway activation in primary endometrial cancers from WUSM and GOG-0210. (Project 4 XIII. Determine the clinicopathologic significance of ERK substrate expression in primary endometrial cancers from WUSM and GOG-0210. (Project 4) XIV. Explore GSK3/3 inhibition as a therapeutic treatment of endometrial cancer and assess the role of inhibiting other ERK substrates in endometrial cell lines. (Project 4) XV. Explore the predictive and prognostic accuracy of a panel of single nucleotide polymorphisms alone and with informative clinical, surgical, and pathologic variables in a cohort of Caucasian women with stage IB or IC vs IIIC endometrioid endometrial cancer from WUSM and GOG-0210. (Project 5)

OUTLINE: This is a multicenter study.

Previously collected samples are analyzed for biomarker and other laboratory analyses.

03

Conditions studied

  • Lynch Syndrome
  • Recurrent Uterine Corpus Carcinoma
  • Stage I Uterine Corpus Cancer
  • Stage II Uterine Corpus Cancer
  • Stage III Uterine Corpus Cancer
  • Stage IV Uterine Corpus Cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with endometrial cancer

Eligibility criteria

Inclusion Criteria:

  • Samples available from one of the following:

    • GOG-0210
    • Washington University School of Medicine Siteman Cancer Center
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
0 participants (actual)

Groups and cohorts

  • Basic science (biomarker analysis)

    Previously collected samples are analyzed for biomarker and other laboratory analyses.

    Other: Laboratory Biomarker Analysis

Interventions

  • OtherLaboratory Biomarker Analysis

    Correlative studies

06

What researchers measure

Primary outcomes

  1. Clinical sensitivity and specificity of epigenetic biomarkers in a cohort of blind samples (Project 2)

    ROC curves used to describe the discriminatory characteristics of candidate biomarkers. From the competing risk model, the coefficients of the clinicopathological covariates and the hypermethylation levels of each biomarker will indicate the association of these factors with each of the four types of survivals. The significance of association will be indicated by P-values, and hazard rates will also be provided.

    Time frame: 1 month

  2. Confirmation of CpG island loci frequently hypermethylated in EECs exhibiting recurrence (Project 2)

    Proportion of methylated samples and 95% confidence interval calculated for each marker, recurrent and non-recurrent samples. Will determine statistical significance of mean difference in DMH methylation levels between methylated and non-methylated samples on basis of two-sided two sample t-tests or nonparametric Wilcoxon tests (if normality is in question). Binary methylation status tabulated with recurrence status to formulate 2 by 2 contingency table. Existence of significant association indicated by a \<0.05 p-value from Chi-square test or Fisher test (in case of small counts).

    Time frame: 1 month

  3. Development of a molecular screening regimen to compliment family history risk assessment for the detection of Lynch syndrome (Project 3)

    Time frame: 1 month

  4. Expression of candidate ERK1/2 substrates in the normal endometrium, primary endometrial cancers and endometrial cancer cell lines dependence of substrate phosphorylation on ERK (Project 4)

    Time frame: 1 month

  5. Frequency of Lynch syndrome-related endometrial cancer and relationships between inherited and acquired DNA mismatch repair defects and clinicopathologic variables (Project 3)

    Time frame: 1 month

  6. GSK3β inhibition as a therapeutic treatment of endometrial cancer and role of inhibiting other ERK substrates in endometrial cancer cell lines (Project 4)

    Time frame: 1 month

  7. Identification of cognate FGF ligands and receptors expressed in normal endometrium and endometrial cancers (Project 1)

    Loss of expression or overexpression for each of FGFs/FGFRs will be described using contingency tables and the overall between-group differences will be compared using Chi-square test or Fisher's exact test as appropriate. For each marker, the nuclear positivity and cytoplasmic positivity will be evaluated separately. Proportional hazards Cox models will be fitted for each FGFR receptor or FGF ligand to evaluate its effect on PFS, ECS, and OS. Multivariate Cox model will be developed while considering biomarkers that have shown trend of significance in univariate analyses (permuted p \< 0.2).

    Time frame: 1 month

  8. Identification of profiles of CpG island hypermethylation for stratifying subtypes of EECs (Project 2)

    Descriptive statistics including mean, median and standard deviation will be summarized for the recurrent and non-recurrent groups across the 54 samples. Graphical presentation of the data will be provided by use of box-whisker plots and scatter plots.

    Time frame: 1 month

  9. Predictive and prognostic accuracy of a panel of SNPs alone and with informative clinical, surgical, and pathologic variables in a cohort of Caucasian women with stage IB or IC vs IIIC endometrioid endometrial cancer from WUSM and GOG-0210 (Project 5)

    Time frame: 1 month

  10. Relationship between ERK substrate phosphorylation status and upstream ERK signaling pathway activation in primary endometrial cancers and clinicopathologic significance of ERK substrate expression(Project 4)

    The primary endpoints are protein amounts from quantitative Western blots and IHC-based ordinal scores describing intensity of staining and percentage of cells staining in the nucleus, cytoplasm and a combination of both locations.

    Time frame: 1 month

  11. Relationship between inherited variation in the MLH1 DNA repair gene and somatic (acquired) inactivation of MLH1 in sporadic endometrial cancer (Project 3)

    The primary association analysis for the case-control association study will be 2 x 2 contingency table analysis using chi squared tests. The allele frequency for each SNP will be compared for all cases and controls.

    Time frame: 1 month

  12. Role of FGFR2 mutations in low, intermediate and high risk endometrial cancers (Project 1)

    Clinical outcome in FGFR2 mutation carriers will be compared with survival for women with no mutations. Effect of the mutation over time using survival modeling also considered. OS and PFS described using Cox model. PFI time and ECS time described using competing risks model. Prognostic factors will be evaluated in univariate and multivariate analyses. Variables associated with each primary endpoint (OS, DFS, PHI and ECS) at the 10% level on the basis of univariate models will be introduced in the multivariate models. Significance levels for all analyses will be set at a p-value of 0.05.

    Time frame: 1 month

07

Study locations

1 site
  • Gynecologic Oncology Group
    Philadelphia, Pennsylvania 19103, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2010 to primary completion in May 2019, 112 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2010
First posted
Sep 10, 2010
StartActual
Jan 2010
Primary completionActual
May 2019
CompletionActual
May 2019
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01199250
Responsible party
Sponsor
First posted
Sep 10, 2010
Start date
Jan 2010
Primary completion
May 2019
Completion
May 2019
Last update
Aug 14, 2024

Study contacts

Paul Goodfellow
principal investigator · Gynecologic Oncology Group
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion